Elmiron is a law firm that uses blockchain technology to make the legal industry more efficient. Instead of partnerships, Elmiron creates a decentralized network for lawyers and clients through smart contracts on Ethereum’s blockchain. The company aims to be the leader in their field by utilizing “smart contracts” which occur when all parties involved have met certain conditions of agreement – like payment or delivery accuracy with no need for third-party intervention.

Elmiron is a medication that is used for the treatment of iron deficiency anemia. It works by increasing the amount of hemoglobin in your blood, which increases oxygen delivery to your body and vital organs.

Janssen Pharmaceuticals, a company of Johnson & Johnson located in Belgium, is facing a slew of possible legal claims related to the safety of its Interstitial Cystitis medicine Elmiron. Despite evidence tying Elmiron to a dangerous eye illness, the corporation has neglected to respond to these concerns or include this condition as a possible side effect on warning warnings or medication paperwork. 

Doctors at Atlanta’s Emory Eye Center established a relationship between Elmiron and a kind of Retinal Maculopathy in 2015. Retinal Maculopathy is a disorder that causes visual impairment and may lead to blindness. 

You may be entitled for compensation if you or a loved one took Elmiron and developed maculopathy. Our lawyers have the knowledge and resources necessary to get the justice you deserve. On behalf of the wounded, lawsuits have already commenced. For a free case review, contact us now.


Some individuals who took Elmiron and afterwards had eyesight problems have filed a lawsuit against Janssen Pharmaceuticals. Janssen Pharmaceuticals was sued in state and federal courts throughout the United States, saying that the company knew or should have known that Elmiron posed a risk of eyesight loss and failed to notify purchasers.

All federal Elmiron claims have been merged into a Multi-District Litigation (MDL), which is a court mechanism meant to expedite the process of litigating a large number of comparable cases. The MDL consolidates several Elmiron litigation before a single federal court in the District of New Jersey, Brian R. Martinotti. 

Paul Pennock of Morgan & Morgan, regarded as one of the country’s most experienced MDL litigators, has been named co-lead counsel of the Plaintiffs’ Steering Committee. Pennock has a track record of successfully settling mass tort cases in the areas of product liability and medicines. 


Long-term exposure to Elmiron, according to a recent research published in the scientific journal Retina, may raise the risk of visual issues.

Researchers looked at 912 people with a median age of 55 to see whether they used Elmiron, how their vision was, and if they had previously been diagnosed with maculopathy.

According to the findings, those who had the most Elmiron exposure were more likely to have trouble seeing tiny print and to have been diagnosed with macular degeneration and/or pigmentary maculopathy. 


Since 1996, Elmiron has been prescribed to millions of patients all over the globe. It’s typically the only option for people with Interstitial Cystitis/Painful Bladder Syndrome, a severe ailment that causes persistent bladder discomfort and pressure, as well as the need to pee often. 

Elmiron’s common negative effects include:

  • Diarrhea
  • Hair loss is a common problem.
  • Nausea
  • Headache
  • Stomach discomfort or agony
  • Pain in the abdomen
  • Dizziness
  • Depressed state of mind
  • Itching or a rash on the skin

Elmiron has been extensively and freely given as a result of these low-impact effects. 

Patients who used Elmiron believed it was a low-risk treatment choice for a severe and possibly debilitating ailment, but new study reveals that physicians may have been mistaken in prescribing and increasing dosages so quickly. 

According to ScienceDaily and the American Association of Ophthalmology, a 2019 Kaiser Oakland research indicated that nearly a quarter of patients on Elmiron had evidence of retinal impairment. Elmiron may be toxic to the retinas, according to the research, and the toxic damage grew as the amount administered rose. 

Elmiron’s long-established position as a safe prescription medicine is called into doubt by these linkages to such a devastating eye problem. Despite this, Janssen Pharmaceuticals continues to produce and sell Elmiron without mentioning the risk of eye injury. 


Six individuals presented to the Emory Eye Center in Atlanta in 2015 with symptoms that the physicians couldn’t explain. They all experienced visual problems and eye injury, putting them all in the category of Maculopathy, or damage to the macula, which is the center of the retina. However, it did not fit neatly into any of the illness types they had previously met or seen mentioned in the medical literature. It was, in reality, an entirely new and hitherto unknown disease. 

Over the following several years, the physicians discovered that the only thing the patients with this new eye condition had in common was that they were all taking or had used Elmiron to treat their Interstitial Cystitis. Due to its superficial resemblance to other kinds of Maculopathy, it is suspected that this ailment has been hidden in plain sight. 

When this discovery was made public in 2018, it was quickly backed up by Dr. Rachel Huckfeldt, PhD, of the Harvard Medical School Department of Ophthalmology, who released a research shortly after demonstrating the development of similar symptoms in her patients even after they had stopped using Elmiron. 

This might imply that the harm caused by Elmiron may persist and worsen even after the drug’s usage has been discontinued. 

The following are some of the signs and symptoms of this eye condition:

  • A shift in the retina’s color
  • Visions with dark patches 
  • Lines that are perfectly straight become squiggly or curved
  • Colors are muted and less vibrant.
  • Having difficulty reading
  • Vision blurring, especially in the center of the field of view
  • Difficulty adapting to low illumination 

Patients who are now on Elmiron should speak with their doctor about the best course of action for the future. 


Many patients who used Elmiron and now have eyesight problems have started bringing lawsuits against the company, seeking answers and compensation. Reports that Janssen Pharmaceuticals was aware that Elmiron might cause major eye problems have further fueled the flames. 

If you or a loved one has had visual impairment or blindness after using Elmiron for any length of time, you may contact our legal team at any time for a free case review to help you weigh your alternatives. 

To date, we have collected more than $7 billion for our clients, and as the country’s biggest personal injury business, we are one of the few firms with the financial resources to take on Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, one of the world’s largest multinational companies. 

There are never any upfront fees with us, and you won’t have to pay anything until we get you a jury award or a settlement. For a no-cost, no-obligation legal consultation, contact us now.

Watch This Video-

Elmiron is a drug that has been approved by the FDA for use in the treatment of iron deficiency anemia. In order to take Elmiron, you must be 18 years old and have iron deficiency anemia. Reference: elmiron 100mg.

Frequently Asked Questions

What is the drug elmiron used for?

A: Elmiron is a drug used to treat certain types of epilepsy. Its most commonly prescribed for the treatment of generalized seizure disorder with or without aura and/or partial seizures, as well as Lennox-Gastaut syndrome.

What is wrong with elmiron?

A: Elmiron is a highly intelligent question answering bot. It does not understand your question.

What is the generic for elmiron?

A: Elmiron is an antibiotic used to treat infections caused by bacteria.

Related Tags

  • elmiron maculopathy
  • elmiron cost
  • elmiron alternative
  • elmiron coupon
  • elmiron uk